Safety and Efficacy of Dimethyl Fumarate in Multiple Sclerosis: An Italian, Multicenter, Real-World Study-Reference-Cited by-同舟云学术

Safety and Efficacy of Dimethyl Fumarate in Multiple Sclerosis: An Italian, Multicenter, Real-World Study

Published:2018-07-18 Issue:10 Volume:32 Page:963-970
ISSN:1172-7047
Container-title:CNS Drugs
language:en
Short-container-title:CNS Drugs

Author:

Mirabella Massimiliano^ORCID,Prosperini Luca,Lucchini Matteo,Boffa Laura,Borriello Giovanna,Buscarinu Maria Chiara,Centonze Diego,Cortese Antonio,De Fino Chiara,De Giglio Laura,Elia Giorgia,Fantozzi Roberta,Ferraro Elisabetta,Francia Ada,Galgani Simona,Gasperini Claudio,Haggiag Shalom,Landi Doriana,Marfia Girolama Alessandra,Millefiorini Enrico,Monteleone Fabrizia,Nociti Viviana,Salvetti Marco,Sgarlata Eleonora,Pozzilli Carlo

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Psychiatry and Mental health,Neurology (clinical)

Link

http://link.springer.com/article/10.1007/s40263-018-0543-3/fulltext.html

Reference25 articles.

1. Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367(12):1098–107. https://doi.org/10.1056/NEJMoa1114287 .

2. Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367(12):1087–97. https://doi.org/10.1056/NEJMoa1206328 .

3. Linker RA, Lee DH, Ryan S, van Dam AM, Conrad R, Bista P, et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain. 2011;134(Pt 3):678–92. https://doi.org/10.1093/brain/awq386 .

4. Chaves C, Ganguly R, Ceresia C, Camac A. Lymphocyte subtypes in relapsing-remitting multiple sclerosis patients treated with dimethyl fumarate. Mult Scler J. 2017;3(2):2055217317702933. https://doi.org/10.1177/2055217317702933 .

5. Longbrake EE, Ramsbottom MJ, Cantoni C, Ghezzi L, Cross AH, Piccio L. Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients. Mult Scler (Houndmills, Basingstoke, England). 2016;22(8):1061–70. https://doi.org/10.1177/1352458515608961 .

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hallmarks of spinal cord pathology in multiple sclerosis;Journal of the Neurological Sciences;2024-01

2. Discontinuation of dimethyl fumarate in multiple sclerosis - a nationwide study;Multiple Sclerosis and Related Disorders;2023-12

3. Impact of adherence to disease-modifying drugs in multiple sclerosis: A study on Italian real-world data;Multiple Sclerosis and Related Disorders;2023-12

4. Effect of disease-modifying treatment on spinal cord lesion formation in multiple sclerosis: A retrospective observational study;Multiple Sclerosis and Related Disorders;2023-11

5. Safety and Discontinuation Rate of Dimethyl Fumarate (Zadiva®) in Patients with Multiple Sclerosis: An Observational Retrospective Study;Journal of Clinical Medicine;2023-07-27